Beijing Tongrentang (600085) H1 2024 earnings summary

Executive summary

• Achieved revenue of ¥9.76 billion for H1 2024, up 0.02% year-over-year; net profit attributable to shareholders was ¥1.02 billion, up 3.49% year-over-year.

• Maintained stable operations amid high prior-year base, with focus on cost control and efficiency improvements.

• Proposed interim cash dividend of ¥0.50 per share (tax included), totaling ¥685.74 million.

Financial highlights

• Revenue: ¥9.76 billion, up 0.02% year-over-year.

• Net profit attributable to shareholders: ¥1.02 billion, up 3.49% year-over-year.

• Operating cash flow: ¥14.75 million, down 99.38% year-over-year due to increased cash outflows for raw material procurement.

• Basic EPS: ¥0.744, up 3.48% year-over-year.

• Gross margin for pharmaceutical manufacturing: 41.39%, down 3.53 percentage points year-over-year.

Outlook and guidance

• Management expects continued stable growth, leveraging brand, product, and industrial advantages.

• Will focus on innovation, digital transformation, and cost control to drive high-quality development.